Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD
April 25, 2025
Discovering and developing innovative therapies to deliver potentially transformative treatments
Over the past several decades, the rapid pace of scientific advancement has catalyzed a revolution in the way we treat cancers. Takeda Oncology │ Leadership │ Article